NewAmsterdam Pharma Company N.V. (NAMS) Soars 5.9%: Is Further Upside Left in the Stock?

NewAmsterdam Pharma Company N.V. (NAMS) shares ended the last trading session 5.9% higher at $32.48. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compares to the stock's 13.6% gain over the past four weeks.The sudden rise in the stock price can be attributed to growing investor optimism regarding the potential of NewAmsterdam Pharma Company’s only investigational candidate, obicetrapib. The candidate is currently being studied as a potential treatment to lower LDL-C as an adjunct to maximally tolerated lipid-lowering therapies in patients with atherosclerotic cardiovascular disease or heterozygous familial hypercholesterolemia across three pivotal late-stage studies.This company is expected to post quarterly loss of $0.41 per share in its upcoming report, which represents a year-over-year change of -127.8%. Revenues are expected to be $2.35 million, down 91.9% from the year-ago quarter.While earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.For NewAmsterdam Pharma Company N.V., the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on NAMS going forward to see if this recent jump can turn into more strength down the road.The stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>NewAmsterdam Pharma Company N.V. belongs to the Zacks Medical - Drugs industry. Another stock from the same industry, Stevanato Group (STVN), closed the last trading session 5.6% lower at $24.53. Over the past month, STVN has returned 7.6%.Stevanato's consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.15. Compared to the company's year-ago EPS, this represents a change of +15.4%. Stevanato currently boasts a Zacks Rank of #2 (Buy).5 Stocks Set to DoubleEach was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%.Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor.Today, See These 5 Potential Home Runs >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report NewAmsterdam Pharma Company N.V. (NAMS): Free Stock Analysis Report Stevanato Group S.p.A. (STVN): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks Weiter zum vollständigen Artikel bei Zacks